MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Senseonics Obtains Significant Coverage Decision

The coverage decision comes on the heels of Senseonics’ rival Dexcom receiving FDA clearance for the G6 Pro Continuous Glucose Monitoring System for healthcare professionals to use with their patients, ages two years and up.

The reach of Senseonics Holdings’ continuous glucose monitoring system became a bit longer. The Germantown, MD-based company announced that Health Care Service Corporation (HCSC) - Blue Cross Blue Shield is now providing coverage for the Eversense CGM System.

This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

“Having HCSC recognize Eversense as one of their covered diabetes management tools demonstrates that more payers are seeing the value that our long-term CGM brings to their members with diabetes,” Tim Goodnow, PhD, president and CEO of Senseonics, said in a release. “Increasing patient access for Eversense has been a top corporate priority and this is a significant milestone in helping us reach approximately 100 million covered lives on our path to widespread insurance coverage. With each new coverage decision, we are able to reduce the financial barriers and help millions of people with diabetes experience the freedom that Eversense brings for up to 90 days of continuous glucose readings.”

Senseonics received FDA approval for Eversense a little more than a year ago. The nod was for a 90-day version of the device. In November of 2018, the company received a nod from FDA that allows qualified healthcare providers to be trained and certified to insert patients with Eversense.

The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends, and alerts.

Senseonics’ coverage decision comes on the heels of Dexcom receiving FDA clearance for the Dexcom G6 Pro CGM System for healthcare professionals to use with their patients, ages two years and up. The pro-version builds off the Dexcom G6, which won a nod from FDA last year.

 

500 characters remaining